Aveanna Healthcare (AVAH - Free Report) reported $478.84 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.1%. EPS of -$0.01 for the same period compares to -$0.03 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $464.33 million, representing a surprise of +3.12%. The company delivered an EPS surprise of +50.00%, with the consensus EPS estimate being -$0.02.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Aveanna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- PDS: $383.45 million versus $371.23 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
- Revenue- MS: $41.29 million versus the three-analyst average estimate of $37.10 million. The reported number represents a year-over-year change of +17.5%.
- Revenue- HHH: $54.10 million compared to the $53.14 million average estimate based on three analysts. The reported number represents a change of -1.1% year over year.
View all Key Company Metrics for Aveanna here>>>Shares of Aveanna have returned +3.7% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Aveanna Healthcare (AVAH - Free Report) reported $478.84 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.1%. EPS of -$0.01 for the same period compares to -$0.03 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $464.33 million, representing a surprise of +3.12%. The company delivered an EPS surprise of +50.00%, with the consensus EPS estimate being -$0.02.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Aveanna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- PDS: $383.45 million versus $371.23 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
- Revenue- MS: $41.29 million versus the three-analyst average estimate of $37.10 million. The reported number represents a year-over-year change of +17.5%.
- Revenue- HHH: $54.10 million compared to the $53.14 million average estimate based on three analysts. The reported number represents a change of -1.1% year over year.
View all Key Company Metrics for Aveanna here>>>Shares of Aveanna have returned +3.7% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Get the latest research report on AVAH - FREE